The treatment resulted in improvements in glycemic control, the lipid profile, anthropometric parameters and visceral and subcutaneous fat content, with reductions in GGT, AST and ALT, as well as hepatic steatosis and the fibrosis index [115]. The gene discussed is GPT; the disease is fatty liver disease.